Morgan Stanley analyst Michael Ulz raised the firm’s price target on Sarepta (SRPT) to $20 from $15 and keeps an Equal Weight rating on the shares after the FDA recommended removal of the voluntary Elevidys hold in ambulatory DMD patients following a quick review. While the firm views the update as “a meaningful positive,” it maintains an Equal Weight rating given a more tempered view on Elevidys, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $40 from $25 at BMO Capital
- Sell Rating for Sarepta Therapeutics Amidst Uncertainty and Financial Risks
- Sarepta price target raised to $5 from 0c at H.C. Wainwright
- Sarepta initiated with a Market Perform at Bernstein
- Sarepta upgraded to Outperform from Perform at Oppenheimer